Special Issue "Vaccine Delivery"
A special issue of Vaccines (ISSN 2076-393X).
Deadline for manuscript submissions: closed (30 June 2015) | Viewed by 78268
Interests: cancer; autoimmunity; mental health; vaccines; exercise
Special Issues, Collections and Topics in MDPI journals
Special Issue in Vaccines: Therapeutic Approaches for Type 1 and Type 2 Diabetes
Special Issue in Brain Sciences: Advances in Multiple Sclerosis Research—Series I
Special Issue in Vaccines: Multiple Sclerosis and Its Complications: Clinical Trials
Special Issue in Brain Sciences: Advances in Multiple Sclerosis Research—Series II
Special Issue in Vaccines: Vaccines for Infectious and Chronic Diseases
Special Issue in Biologics: Anti-SARS-CoV-2/COVID-19 Drugs and Vaccines
Special Issue in Vaccines: Multiple Sclerosis, Complications and Therapeutics 2.0
Special Issue in Molecules: Advances in Research of Short Peptides II
Special Issue in Biologics: Aged Population and Immunocompromised Patients: Impact on SARS-CoV-2 Variants and Treatment Outcomes
Special Issue in Cancers: Mucins and Cancers
Special Issue in Cancers: Checkpoint Markers and Cancer Microenvironment: What Do We Know?
Special Issue in International Journal of Molecular Sciences: Chronic Diseases: Gut-Brain-Immune-Microbiome Axis
Special Issue in International Journal of Molecular Sciences: Mechanisms and Interventions for Neurological and Psychological Disorders
Special Issue in Vaccines: Vaccines for Infectious and Chronic Diseases 2.0
Special Issue in Biomedicines: Bioactive Compounds in Chronic Diseases
Special Issue in International Journal of Molecular Sciences: Mechanisms and Interventions for Neurological and Psychological Disorders 2.0
Special Issue in Biologics: Anti-SARS-CoV-2/COVID-19 Drugs and Vaccines: Part II
Special Issue in Viruses: SARS-CoV-2: Vaccine Design and Host Immunity
Topics: Inflammation: The Cause of All Diseases
Topics: Recent Advances in Healthy Ageing
Topics: Inflammation: The Cause of all Diseases 2.0
Over 1,000 years ago in China, contents of smallpox vesicles were injected into people who had not previously experienced smallpox. Fatalities were uncommon in the individuals inoculated with the smallpox vesicles, compared with victims of natural smallpox infection. More than 700 years later, Edward Jenner injected an 8 year old boy with cowpox and challenged him with smallpox, the boy was subsequently protected against smallpox. Hence the term “cross reactivity” was coined. Two hundred year later, smallpox vaccination became increasingly popular in the decade 1967-1977 and complete world-wide eradication was accomplished. Numerous methods of vaccination have been used, such as, attenuated bacteria, live virus’s, dead organisms and despite their success, a number of disasters in humans have resulted. Disasters were primarily due to improper lab manufacturing and handling and consequently these incidences led to improved procedures and the safety of vaccines, and led to regulatory measures to assure proper laboratory conditions. With attempts to control more complex diseases and the need to improve vaccine safety, stability, efficacy and cost, there is pressure for precisely defined vaccines.
Public awareness of health and safety issues vaccines must now meet higher standards of safety and biochemical characterization than they did in the past. Some of the vaccines developed in the past would not even meet the minimum standards required today. Hence, new improved precisely defined highly purified vaccines need to be developed. Advances in the fields of peptide synthesis, molecular biology, protein production, immunology, animal models etc are required for the development of new and improved vaccines, in an attempt to move from traditional live virus vaccines to the theoretical safer but ‘less immunogenic’ vaccines. In an attempt to improve the immunogenicity of the highly purified vaccines, a number of technologies and delivery methods have been utilized. This special issue will present, delivery methods used to improve immunogenicity of vaccines, and their in vitro and in vivo biological activities with the aim to go into human clinical trials.
Prof. Dr. Vasso Apostolopoulos
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Vaccines is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2700 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.